ArticleInternational urology and nephrology2026
Oncologic outcomes and prognostic significance of lymphovascular invasion in renal cell carcinoma according to nodal stage.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeTo assess the prognostic significance of lymphovascular invasion (LVI) in patients with renal cell carcinoma (RCC), stratified by nodal status (N0 vs. N1), and to evaluate its influence on survival and perioperative outcomes. MATERIALS AND
methodsA retrospective review was conducted of 2787 patients with clinical T1-2 RCC who underwent nephrectomy at a single tertiary center. Patients were categorized by LVI status and pathologic nodal stage (N0 or N1). Clinicopathological features, perioperative outcomes, and oncologic endpoints-including recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS)-were analyzed using Kaplan-Meier analysis and Cox proportional hazards models.
resultsAmong N0 patients, LVI-positive tumors were associated with adverse preoperative markers, higher Fuhrman grades, larger tumor sizes, and poorer perioperative outcomes. These associations were not observed in N1 patients. Kaplan-Meier analysis demonstrated significantly lower RFS, DSS, and OS among patients with LVI in the N0 group (all p < 0.001), but not in the N1 group. In multivariable analysis for N0 patients, LVI remained an independent predictor of OS (hazard ratio 1.804, 95% confidence interval 1.107-2.939, p = 0.018).
conclusionsLVI is a significant prognostic factor for recurrence and survival in node-negative RCC, but not in node-positive disease. These results support a stage-dependent interpretation of LVI and its incorporation into postoperative surveillance and individualized risk stratification for patients with low-stage RCC.
Indexed as
Identifiers
42000936What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.